

Docket No. 366325-120
US App. No. 09/340,338

IN THE CLAIMS

1-42. (Canceled)

2

43. (Currently amended) The delivery device of claim [42] ¹~~42~~, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer.

8

44. (Currently amended) [The delivery device of claim 43,] A delivery device for treatment of erectile dysfunction in a patient, comprising a disk, wherein the disk is made of a mixture of materials comprising a filmogenic polymer and an effective dose of a therapeutic agent suitable for treating erectile dysfunction, wherein the device does not comprise a backing layer, wherein the device does not comprise a release liner, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer, and wherein the disk comprises 70 to 95 wt% filmogenic polymer.

9

45. (Previously presented) The delivery device of claim ⁸~~44~~, wherein the filmogenic polymer is polyvinyl pyrrolidone.

10

46. (Previously presented) The delivery device of claim ⁸~~44~~, wherein the filmogenic polymer is gliadin.

11

47. (Currently amended) The delivery device of claim [42] ⁸~~44~~, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

12

48. (Currently amended) The delivery device of claim [42] ⁸~~44~~, wherein the therapeutic agent is selected from the group consisting of prostaglandin, a testosterone, a

Docket No. 366325-120
US App. No. 09/340,338

yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxisylyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

1 49. (Currently amended) [The delivery device of claim 42,] A delivery device for treatment of erectile dysfunction in a patient, comprising a disk, wherein the disk is made of a mixture of materials comprising a filmogenic polymer and an effective dose of a therapeutic agent suitable for treating erectile dysfunction, wherein the device does not comprise a backing layer, wherein the device does not comprise a release liner, and wherein the therapeutic agent is misoprostol.

13 50. (Currently amended) The delivery device of claim [42] ⁸/~~44~~, wherein the therapeutic agent is a prostaglandin.

14 51. (Previously presented) The delivery device of claim ¹³/~~50~~, wherein the therapeutic agent is prostaglandin E1.

3 52. (Currently amended) The delivery device of claim [42] ¹/~~48~~, wherein the disk further comprises a plasticizer in an amount of less than 30 wt%.

4 53. (Previously presented) The delivery device of claim ³/~~52~~, wherein the plasticizer is a polyethylene glycol (PEG).

5 54. (Previously presented) The delivery device of claim ⁴/~~53~~, wherein the polyethylene glycol is PEG 400.

6 55. (Currently amended) The delivery device of claim [42] ¹/~~49~~, wherein the delivery device is a transdermal device.

Docket No. 366325-120
US App. No. 09/340,338

7 56. (Currently amended) The delivery device of claim [42] ¹~~42~~, wherein the delivery device is a transmucosal device.

15 57. (Previously presented) A delivery device for the treatment of erectile dysfunction in a patient, comprising a disk, wherein the disk is made of a mixture of materials comprising a filmogenic polymer and an effective dose of a therapeutic agent suitable for treating erectile dysfunction, wherein the disk comprises 70 to 95 wt% filmogenic polymer.

17 58. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the filmogenic polymer is polyvinyl pyrrolidone.

18 59. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the therapeutic agent is misoprostol.

19 60. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the therapeutic agent is a prostaglandin.

20 61. (Previously presented) The delivery device of claim ¹⁹~~60~~, wherein the prostaglandin is prostaglandin E1.

21 62. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the mixture of materials further comprises a plasticizer in an amount of less than 30 wt%.

22 63. (Previously presented) The delivery device of claim ²¹~~62~~, wherein the plasticizer is a polyethylene glycol (PEG).

23 64. (Previously presented) The delivery device of claim ²²~~63~~, wherein the polyethylene glycol is PEG 400.

Docket No. 366325-120
US App. No. 09/340,338

24

65. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the delivery device is a transdermal device.

25

66. (Previously presented) The delivery device of claim ¹⁵~~57~~, wherein the delivery device is a transmucosal device.

28

67. (Previously presented) A delivery device for the treatment of erectile dysfunction in a patient, comprising a disk, wherein the disk is made of a mixture of materials comprising 90 to 95 wt% polyvinyl pyrrolidone and an effective dose of a therapeutic agent suitable for treating erectile dysfunction.

31

68. (Previously presented) The delivery device of claim ²⁸~~67~~, wherein the therapeutic agent is misoprostol.

32

69. (Previously presented) The delivery device of claim ²⁸~~67~~, wherein the therapeutic agent is a prostaglandin.

33

70. (Previously presented) The delivery device of claim ³²~~69~~, wherein the prostaglandin is prostaglandin E1.

34

71. (Previously presented) The delivery device of claim ²⁸~~67~~, wherein the mixture of materials further comprises a plasticizer.

35

72. (Previously presented) The delivery device of claim ³⁴~~71~~, wherein the plasticizer is a polyethylene glycol (PEG).

36

73. (Previously presented) The delivery device of claim ³⁵~~72~~, wherein the polyethylene glycol is PEG 400.

Docket No. 366325-120
US App. No. 09/340,338

37 74. (Previously presented) The delivery device of claim ²⁶~~67~~, wherein the delivery device is a transdermal device.

38 75. (Previously presented) The delivery device of claim ²⁶~~67~~, wherein the delivery device is a transmucosal device.

39 76. (Previously presented) A delivery device for the treatment of erectile dysfunction in a patient, comprising a disk, wherein the disk is made of a mixture of materials comprising 90 to 95 wt% polyvinyl pyrrolidone, an effective dose of a therapeutic agent suitable for treating erectile dysfunction and a plasticizer, wherein the device does not comprise a backing layer and wherein the device does not comprise a release liner.

40 77. (Previously presented) The delivery device of claim ³⁹~~76~~, wherein the therapeutic agent is misoprostol and the plasticizer is PEG 400.

41 78. (Previously presented) The delivery device of claim ³⁹~~76~~, wherein the therapeutic agent is a prostaglandin.

42 79. (Previously presented) The delivery device of claim ⁴¹~~78~~, wherein the prostaglandin is prostaglandin E1.

45 80. (Previously presented) A delivery device for the treatment of erectile dysfunction in a patient, comprising a disk; wherein the disk is made of a mixture of materials comprising 70 to 95 wt% filmogenic polymer, an effective dose of a therapeutic agent suitable for treating erectile dysfunction, and at least one additive selected from the group consisting of a stabilizer, a solubilizer, and enhancer and a plasticizer.

46 81. (Previously presented) The delivery device of claim ⁴⁵~~80~~, wherein the at least one additive comprises an enhancer selected from the group consisting of a

Docket No. 366325-120
US App. No. 09/340,338

glycolipid, a non-esterified fatty acid, an aliphatic alcohol, a fatty acid ester of an aliphatic alcohol, a cyclohexanol, a fatty acid ester of glyccrol, a glycol, an aliphatic alcohol ether of a glycol, and a surfactant.

47 82. (Previously presented) The delivery device of claim ⁴⁵80, wherein the therapeutic agent is a prostaglandin.

48 83. (Previously presented) The delivery device of claim ⁴⁷82, wherein the prostaglandin is prostaglandin E1.

49 84. (Previously presented) The delivery device of claim ⁴⁷82, wherein the at least one additive comprises a plasticizer.

50 85. (Previously presented) The delivery device of claim ⁴⁹84, wherein the plasticizer is a polyethylene glycol.

54 86. (Previously presented) A method of treating erectile dysfunction, comprising:

- selecting a device comprising a disk, wherein the disk is made of a mixture of materials comprising a filmogenic polymer and an effective dose of a therapeutic agent suitable for treating erectile dysfunction, wherein the disk comprises 70 to 95 wt% filmogenic polymer, wherein the device does not comprise a backing layer and wherein the device does not comprise a release liner;

- wetting a penile surface; and

- placing the device in contact with the wetted surface, thereby wetting the disk and delivering the at least one therapeutic agent to the penile surface in a time period that is desirable to obtain a positive response.

55 87. (Previously presented) The method according to claim ⁵⁴86, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle

Docket No. 366325-120
US App. No. 09/340,338

relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

56 88. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the therapeutic agent is selected from the group consisting of a prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

57 89. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the therapeutic agent is present in a range of 0.1-15 wt%.

58 90. (Previously presented) The method according to claim ⁵⁶~~88~~, wherein the therapeutic agent is misoprostol.

59 91. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the plasticizer is present in an amount that is less than 30 wt%.

60 92. (Previously presented) The method according to claim ⁵⁹~~91~~, wherein the plasticizer is a polyethylene glycol (PEG).

61 93. (Previously presented) The method according to claim ⁶⁰~~92~~, wherein the polyethylene glycol is PEG 400.

62 94. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the filmogenic polymer is a synthetic polymer.

63 95. (Previously presented) The method according to claim ⁶²~~94~~, wherein the synthetic polymer is polyvinyl pyrrolidone.

Docket No. 366325-120
US App. No. 09/340,338

65 96. (Currently amended) The method according to claim ⁶⁴~~86~~ 122, wherein the filmogenic polymer is a plant protein.

66 97. (Previously presented) The method according to claim ⁶⁵~~96~~, wherein the plant protein is a prolamine.

67 98. (Previously presented) The method according to claim ⁶⁶~~97~~, wherein the prolamine is a gliadin.

68 99. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the time period is 5-100 minutes.

69 100. (Previously presented) The method according to claim ⁶⁸~~99~~, wherein the time period is 30-60 minutes.

70 101. (Previously presented) The method according to claim ⁵⁴~~86~~, wherein the penile surface is selected from the group consisting of (a) the shaft, (b) the glans and (c) both the shaft and the glans.

71 102. (Previously presented) A method of treating erectile dysfunction, comprising:

selecting a device comprising a disk, wherein the disk is made of a mixture of materials, wherein the disk is made of a mixture of materials comprising 90 to 95 wt% polyvinyl pyrrolidone, polyethylene glycol and an effective dose of misoprostol suitable for treating erectile dysfunction;

wetting a penile surface; and

placing the device in contact with the wetted surface, thereby wetting the disk and delivering the at least one therapeutic agent to the penile surface in a time period that is desirable to obtain a positive response.

Docket No. 366325-120
US App. No. 09/340,338

72

103. (Previously presented) The method according to claim ~~102~~⁷¹, wherein the penile surface is selected from the group consisting of (a) the shaft, (b) the glans and (c) both the shaft and the glans.

26

104. (New) The delivery device of claim ~~57~~¹⁵, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

27

105. (New) The delivery device of claim ~~57~~¹⁵, wherein the therapeutic agent is selected from the group consisting of prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

29

106. (New) The delivery device of claim ~~57~~²⁸, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

30

107. (New) The delivery device of claim ~~57~~²⁸, wherein the therapeutic agent is selected from the group consisting of prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

44

108. (New) The delivery device of claim ~~76~~³⁹, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

Docket No. 366325-120
US App. No. 09/340,338

43 109. (New) The delivery device of claim ³⁹~~76~~, wherein the therapeutic agent is selected from the group consisting of prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

53 110. (New) The delivery device of claim ⁴⁸~~80~~, wherein the therapeutic agent is selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

62 111. (New) The delivery device of claim ⁴⁵~~80~~, wherein the therapeutic agent is selected from the group consisting of prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

64 112. (New) The delivery device of claim ⁵⁴~~86~~, wherein the filmogenic polymer is a naturally occurring polymer.

16 113. (New) The delivery device of claim ¹⁵~~51~~, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer.

51 114. (New) The delivery device of claim ⁴⁵~~80~~, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer.